The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma

Annals of Oncology

Volumn 27, Issue 6, 2016, Pages 1174-1177

  Lee, B ^a,c,d   Wong, A ^a   Kee, D ^a   Neeson, P ^a,d   Shackleton, M ^a,d   McArthur, G ^a,b,d   Sandhu, S ^a,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b Walter and Eliza Hall Institute of Medical Research   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; IPILIMUMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; SALAZOSULFAPYRIDINE; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; AGED; CLINICAL ARTICLE; COLITIS; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; EYE MELANOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIAGNOSTIC IMAGING; MELANOMA; RETROSPECTIVE STUDY; SKIN TUMOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ARTHRITIS, RHEUMATOID; CTLA-4 ANTIGEN; FEMALE; HUMANS; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 84974824082     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw056     Document Type: Letter

References (14)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
3. Schadendorf D, Hodi FS, Robert C,et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33: 1889-1894.
4. Kormendy D, Hoff H, Hoff P, et al. Impact of the CTLA-4/CD28 axis on the processes of joint inflammation in rheumatoid arthritis. Arthritis Rheum 2013; 65: 81-87.
5. Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci USA 2008; 105: 19396-19401.
6. Seidl C, Donner H, Fischer B, et al. CTLA4 codon 17 dimorphism in patients with rheumatoid arthritis. Tissue Antigens 1998; 51: 62-66.
7. Pieper J, Herrath J, Raghavan S, et al. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol 2013; 14: 34.
8. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-2581.
9. Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015; 33: 3193-3198.
10. Arriola E, Wheater M, Karydis I, et al. Infliximab for IPILIMUMAB-related colitisletter. Clin Cancer Res 2015; 21: 5642-5643.
11. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532.
12. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34.
13. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006-2017.
14. Alexander M, Mellor JD, McArthur G, Kee D. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma. Med J Aust 2014; 201: 49-53.